Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

In this video interview, Heather Horville, solutions consultant at Greenphire, discusses how growing financial and logistical ...

How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical ...

Applied Clinical Trials is the thought leader in pharmaceutical drug development operations and clinical trial design, management, and monitoring.

In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

Why future-ready pharma companies must embrace AI-driven, real-time decision-making. Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how AI is stepping in to fill staffing gaps in ...

With technology/AI taking over administrative and repetitive tasks, human roles will shift towards more strategic, creative, ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.